Please assess the completion status of the following clinical trial:

Trial Title: PTCy and Ruxolitinib GVHD Prophylaxis in Myelofibrosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have an indication for allogeneic hematopoietic stem cell transplantation~* Diagnosis:~Primary myelofibrosis Secondary myelofibrosis~* Signed informed consent~* Matched related, 8-10/10 HLA-matched unrelated or haploidentical donor available. The HLA typing is performed by the following genetic loci: HLA-A, HLA-B, HLA-Cw, HLA-DRB1, and HLA-DQB1.~* No second tumors~* No severe concurrent illness~Exclusion Criteria:~* Moderate or severe cardiac dysfunction, left ventricular ejection fraction \<50%~* Moderate or severe decrease in pulmonary function, FEV1 \<70% or DLCO\<70% of predicted~* Respiratory distress \>grade I~* Severe organ dysfunction: AST or ALT \>5 upper normal limits, bilirubin \>1.5 upper normal limits, creatinine \>2 upper normal limits~* Creatinine clearance \< 60 mL/min~* Uncontrolled bacterial or fungal infection at the time of enrollment~* Requirement for vasopressor support at the time of enrollment~* Karnofsky index \<30%~* Pregnancy~* Somatic or psychiatric disorder making the patient unable to sign informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- PTCy and ruxolitinib (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).